Compare Howmet Aerospace Inc (HWM) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Howmet Aerospace Inc vs Novo Nordisk A/S — how do they compare? Howmet Aerospace Inc trades at $282.56 (market cap $112.20B), while Novo Nordisk A/S trades at $46.43 (market cap $207.85B). The key difference: Novo Nordisk A/S is the larger of the two by market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| HWM | NVO | |
|---|---|---|
Market Cap | $112.20B | $207.85B |
Sector | Industrials | Health |
52-Week High | $291.28 | $63.98 |
52-Week Low | $171.00 | $35.29 |
Enterprise Value | $116.30B | $222.55B |
Dividend Yield | 0.2% | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Howmet Aerospace (HWM) trades at $281.63, down 0.73% on the day, with strong technical support at $279 and resistance at $285. The company has consistently beaten earnings estimates, with Q2 2026 EPS of $1.33 exceeding expectations by 7.3%, driven by robust aerospace and defense demand. Analyst consensus remains strongly bullish with 84% buy ratings and a $334.63 price target, representing 19% upside potential.
Outlook remains positive with raised 2026 guidance and strong cash flow generation, though elevated valuation multiples (P/E 60.63) and significant capital expenditures present risks. The stock offers growth exposure to aerospace recovery but faces execution risks amid capacity expansion plans and supply chain challenges.
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Howmet Aerospace Inc
Howmet Aerospace provides advanced engineered solutions for the aerospace and transportation industries. It specializes in jet engine components, aerospace fastening systems, and forged aluminum wheels.
Read more on HWM →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
